Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease.

ABSTRACT:

Background

Parkinson's disease (PD) is the second most prevalent neurodegenerative disease characterized by motor impairment resulting from the degeneration of dopaminergic neurons in the substantia nigra, alongside α -synuclein (α-syn) accumulation, mitochondrial dysfunction, and oxidative stress. Recent studies on PD treatment have focused primarily on exploring oxidative stress and mitochondrial function as ways to restore dopamine release. Notably, previous studies have demonstrated that Paraoxonase 2 (PON2) plays a critical role in neuroprotection and neuroinflammation by reducing oxidative stress in striatal neurons and astrocytes.

Methods

In this study, we investigated the potential therapeutic effect of a newly developed drug, Vutiglabridin, which is demonstrated to

SUBMITTER: An H 

PROVIDER: S-EPMC12535076 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature